tldrdailynews.com logo

AstraZeneca and Baxdrostat unveil promising new treatments for resistant hypertension

1 min read
Source: Reuters
AstraZeneca and Baxdrostat unveil promising new treatments for resistant hypertension
Photo: Reuters
TL;DR

AstraZeneca plans to seek regulatory approval for its experimental blood pressure drug, baxdrostat, by the end of the year, aiming for potential approval in 2026 in the US and EU. The drug targets the hormone aldosterone and has shown promising results in reducing systolic blood pressure, with peak sales expected to exceed $5 billion. A small percentage of patients experienced hyperkalaemia.

Topics:top-newshealth#astrazeneca#baxdrostat#blood-pressure#drug-approval#health#hypertension
Share this article
  1. AstraZeneca to seek approval for blood pressure drug by year-end  Reuters
  2. There may soon be a new approach to treat hard-to-control high blood pressure  CNN
  3. New drug hailed as ‘gamechanger’ in tackling stubbornly high blood pressure  The Guardian
  4. BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension  TCTMD.com
  5. New blood pressure pill ‘lowers risk of heart problems in 12 weeks’  The Independent

Want the full story? Read the original reporting

Read on Reuters